摘要
目的:了解接受肿瘤坏死因子拮抗剂治疗强直性脊柱炎临床常见不良反应及少见不良反应。方法:本组选取了50例强直性脊柱炎患者接受肿瘤坏死因子拮抗剂(本组均选用上海中信科健公司产品益赛普)治疗,同时观察不良反应发生率及常见不良反应症状。结果:接受肿瘤坏死因子拮抗剂治疗的50例患者发生首次不良反应的有8例,中长期不良反应5例。结论:生物制剂治疗强直性脊柱炎是安全有效的,但应注意不良反应的发生及处置。
Objective：To learn about the common and the rare adverse reactions taking place in the clinical treatment of ankylosing spondylitis with tumor necrosis factor （TNF） antagonist.Method：50 cases of patients were enrolled in this group receiving TNF antagonist （the product used in this group was Etanercept from Shanghai CP Guojian Pharmaceutical Co,Ltd） for treating ankylosing spondylitis.In addition,the incidence of adverse reactions and the common reverse reactions were observed.Result：Of the 50 patients received TNF antagonist for treating ankylosing spondylitis,first-dosage adverse reactions occurred in eight cases and medium or long-term adverse reactions occurred in 5 cases.Conclusion：The usage of biological agent in the treatment of ankylosing spondylitis is considered as a safe and efficacious approach,in which the occurrence and management of the adverse reactions should be concerned.
出处
《中国医学创新》
CAS
2012年第28期37-38,共2页
Medical Innovation of China
